All In Biotech

Drug Trial Radar · NCT01296711

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

A Phase 2, Multicenter, Open-Label, Follow-up Study to Assess the Long-Term Safety and Efficacy of CDP6038 (Olokizumab) Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis Who Completed Study RA0056

Last checked: Nov 20, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

190

Actual

Start

Mar 7, 2011

Primary completion

May 1, 2013

Study completion Aug 5, 2013

Sponsor

Lead sponsor
UCB BIOSCIENCES, Inc.UCB
Sponsor type
Industry
Collaborators
R-Pharm
First posted
Feb 15, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).

Conditions

  • Rheumatoid Arthritis

Interventions

  • CDP6038 (olokizumab)Biological

    100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Treatment-emergent Adverse Events (TEAEs)Time frame: From Baseline (Week 0 of Study RA0057) until 30 days after the last dose (maximum up to 780 days)

Locations

55 sites in 3 countries. Site status is shown where the registry gives one.

  • 166

    Mesa, Arizona

  • 154

    Phoenix, Arizona

  • 118

    Scottsdale, Arizona

  • 103

    Hot Springs, Arkansas

  • 127

    Covina, California

  • 148

    La Jolla, California

  • 184

    Long Beach, California

  • 177

    Los Angeles, California

  • 104

    Palo Alto, California

  • 129

    Santa Maria, California

  • 164

    Upland, California

  • 141

    Hamden, Connecticut

  • 111

    Lewes, Delaware

  • 151

    DeBary, Florida

  • 114

    Jupiter, Florida

  • 157

    Tampa, Florida

  • 183

    Tampa, Florida

  • 116

    Idaho Falls, Idaho

  • 160

    Moline, Illinois

  • 168

    Springfield, Illinois

  • 133

    Cedar Rapids, Iowa

  • 172

    Kansas City, Kansas

  • 185

    Saint Clair Shores, Michigan

  • 112

    St Louis, Missouri

  • 134

    St Louis, Missouri

  • 102

    Lincoln, Nebraska

  • 171

    Freehold, New Jersey

  • 152

    Toms River, New Jersey

  • 174

    Brooklyn, New York

  • 170

    Charlotte, North Carolina

  • 150

    Cincinnati, Ohio

  • 100

    Dayton, Ohio

  • 110

    Oklahoma City, Oklahoma

  • 165

    Duncansville, Pennsylvania

  • 105

    Nashville, Tennessee

  • 135

    Austin, Texas

  • 128

    Dallas, Texas

  • 126

    Houston, Texas

  • 132

    Houston, Texas

  • 138

    Houston, Texas

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.